Prophylactic effect of herbal-marine compound (HESA-A) on influenza A virus infectivity

BMC Complementary and Alternative Medicine

Mohd Hair-Bejo¹  Abdul Rahman Omar¹  Aini Ideris¹  Parvaneh Mehrbod¹ 

[1] Institute of Bioscience, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia

关键词: MTT;    HA;    Influenza virus;    H1N1;    HESA-A;   

Others  :  1220192
DOI  :  10.1186/1472-6882-14-131

 received in 2013-09-19, accepted in 2014-03-31,  发布年份 2014

【 摘 要 】

Background

Influenza virus is still a severe respiratory disease affecting human and other species. As conventional drugs are not recommended for long time because of side effects and drug resistance occurrence, traditional medication has been focused as alternative remedy. HESA-A is a natural compound from herbal-marine origin. Previous studies have reported the therapeutic properties of HESA-A on psoriasis vulgaris and different types of cancers and we also showed its anti-inflammatory effects against influenza A infection.

Methods

This study was designed to investigate the potential properties of HESA-A as prophylaxis or treatment. To investigate the prophylaxis or treatment activities of HESA-A, Madin-Darby Canine Kidney (MDCK) cells were exposed to HESA-A and influenza A virus in different manners of exposure and different time intervals. The results were evaluated by MTT and HA assays.

Results

It was found that HESA-A is much more effective against influenza cytopathic effects when it is applied for prophylaxis and also in concurrent treatment (p ≤ 0.05) but not in post-infection treatment (p ≥ 0.05).

Conclusion

In conclusion, HESA-A is significantly effective against influenza replication in prophylaxis application affecting the virus penetration/adsorption to the cell without any toxic effect on the cell viability.

【 授权许可】

   
2014 Mehrbod et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sarah CD, Hong M: Amantadine-induced conformational and dynamical changes of the influenza M2 transmembrane proton channel. Proc Natl Acad Sci USA 2008, 105:1483-1488.
• [2]Calero M, Chen CZ, Zhu W, Winand N, Havas KA, Gilbert PM, Burd CG, Collins RN: Dual prenylation is required for Rab protein localization and function. Mol Biol Cell 2003, 14:1852-1867.
• [3]Wagman PC, Leong MA, Simmen KA: Development of a novel influenza A antiviral assay. J Virol Method 2002, 105:105-114.
• [4]Dai J-P, Li W-Z, Zhao X-F, Wang G-F, Yang J-C, Zhang L, Chen X-X, Xu Y-X, Li K-S: A drug screening method based on the autophagy pathway and studies of the mechanism of evodiamine against influenza A virus. PLoS One 2012, 7:e42706.
• [5]Pathumwadee I, Chittima L, Thanyada R, Arthorn L, Maturos M, Panita D, Ornjira A, Krit C, Nopphorn K, Pornthep S, Somsak P, Supot H: How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model 2008, 27:342-348.
• [6]Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki T, Mootrey G, Bresee JS, Cox NJ: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Recomm Report 2008, 57:1-60.
• [7]Moallem S, Ahmadi A, Moshafi M, Taghavi M: Evaluation of fetal toxicity of HESA-A, a natural anticancer agent, in mice. J Kerman Med Sci 2007, 14:124-133.
• [8]Ahmadi A, Balali-Mood K, Ghafghazi T, Rajabi P, Taher M: Toxicity evaluation of an antitumor marine compound (HESA-A) in mice and rats. J Birjand Univ Med Sci 2005, 12:3-18.
• [9]Ahmadi A, Barikbin B, Naseri M, Mohagheghi M: The effect of HESA-A on psoriasis vulgaris. J Drug Dermatol 2008, 7:559-561.
• [10]Ahmadi A, Mohagheghi MA, Fazeli MS, Nahavandian B, Bashardoost N, Musavi JA, Gharipoor M: HESA-A, a new treatment for breast cancer and choroidal metastasis. Med Sci Monit 2005, 11:CR300-CR303.
• [11]Mehrbod P, Ideris A, Omar AR, Hair-Bejo M, Tan SW, Kheiri MT, Tabatabaian M: Attenuation of influenza virus infectivity with herbal-marine compound (HESA-A): an in vitro study in MDCK cells. Virol J 2012, 9:44. BioMed Central Full Text
• [12]Sadeghi AH, Ahmadi A: Cytotoxicity and antitumor properties of a marine compound, HESA-A, on cancer cells. DARU 2003, 11:82-87.
• [13]Mehrbod P, Motamed N, Tabatabaian M, Soleimani Estyar R, Amini E, Shahidi M, Kheiri MT: In vitro antiviral effect of "Nanosilver" on influenza virus. DARU 2009, 17:88-93.
• [14]Rossman JS, Lamb RA: Autophagy, apoptosis, and the influenza virus M2 protein. Cell Host Microbe 2009, 6:367-380.
• [15]Fedson DS: Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Inf Dis 2006, 43:199-205.
• [16]Kitazato K, Wang Y, Kobayashi N: Viral infectious disease and natural products with antiviral activity. Drug Discov Ther 2007, 1:14-22.
• [17]Vahabpour RR, Shamsi SM, Monavari SH, Sajjadi SEN: Evaluation of potential antiviral activity of hydroalcoholic extract of lemon balm L. against herpes simplex virus type-I. Iran J Virol 2007, 1:28-32.
• [18]Ahmadi A: A study of thirty patients with metastatic liver cancer and hepatocellular carcinoma treated with HESA-A. In Fifth AACR International Conference on Frontiers in Cancer Prevention Research. USA: AACR Meeting Abstracts Online; 2006.